Member Info for Hurst10

Read the RNS, to acquire a property .

Dated 5/10

Worth remenbering it is an Omega announcement is an antibody contract not antigen.
We will have the CE approval for a saliva based rapid antigen test in due course ,but we should focus on the timing of the BAMS approval which could be any day. Anything you can get below friday's close should be bought, because of the up coming news flow.

On the market earliest August 2021

ie. the manufacturing partners have been told, all ok to commit substantial working capital to invest in order to be ready!

The absence of any negative RNS ref the trials

My point was, that if that had been any regulatory issues with the clinical data from the BAMS and rapid antigen testing trials, Avacta would have had to release a RNS as it would have been highly price sensitive.
Since we have had no such thing and the company continue to sign up manufacturing partners who have to commit capital to buy relevant plastic etc to meet demand, then we will have to assume , as. the company ref BAMS have indicated further news is imminent, that we are heading for a very exciting next week, with some help from Bruker on Monday, speaking about their progress on Covid 19 in a webinar to investors( on their web site )

Hope so.
Interesting to see what the offer price at the opening.
Watch post market prints

Another important point is,that if there had been any Regulatory issues with BAMS and indeed with the rapid Covid antigen saliva based test, the company would have to issue a RNS by now, as it is highly Price sensitive. Now the company has not done this and as the company have signed up manufacturing partners and will continue to do so, we can safely assume we are heading for a very positive next two weeks

Interesting read;
Hedge Funds Never Been This Bullish On Bruker Corporation (BRKR)
Bruker Corporation (NASDAQ:BRKR) investors should pay attention to an increase in hedge fund sentiment recently. Bruker Corporation (NASDAQ:BRKR) was in 28 hedge funds' portfolios at the end of the second quarter of 2020. The all time high for this statistics is 27. This means the bullish number of hedge fund positions in this stock currently sits at its all time high.
Awaiting end of Q3 Numbers, the likes of D E Shaw holds $36 mill in Bruker.
Clearly the major hedge funds likes Bruker and what they are doing and with BAMS about to make the headlines ( read Avacta), we will have a substantial increase of interest in Avacta from major US hedge funds, but also from major US Money managers as they folllow the leading hedgefunds as they consistently outperform the S&P.
Exciting week ahead.
We have seen consistently interest in buying most afternoons.

House broker keeping a low profile on the offer ( no Stock )

However our oxford friends will not a finished product on the market till August 2021, earliest. In the announcement.
Meanwhile Avacta will be on the market in October / November and dealing with several billions of demand.
It is Friday, very dangerous to be short going into the week end.
Note the house broker is again on the bid but far away from the offer.
Monday Webinar by our US partner on Covid

Gents,
Great more capacity poyential coming to the market in the middle of 2021.
Germany ordering Rapid tests from Roche,Siemens and Abbott,good for them.One small problem there is no capacity to meet even a quarter of the demand. What we do have to encourage, is that they all work together, but what we also have to acknowledge is that our company have a rapid antigen salivia based 5 min test coming to the market, with only one other "competitor" being Abbott, who cannot cope with demand and have admitted that.You need to stand back and face the facts,Avacta will by next year make billions in revenues with substantial margins and still would not meet demand.Once approved by CE for professional use, UK government will demand 400 mill immidiately. Avacta have manufacturing partners signed up and several more sitting on the bench waiting.With full MHRA approval for comsumer use, we are taking about demand which is Beyond any estimates out there.There will be no fully approved vaccine avaible till Q2 or Q3 at the earliest.If we look beyond BAMS and rapid testing, the market for Affimer is amazing and with AVA6000 phase 1 trials kicking off,well you try and apply EBITDA est.
The manufacturing partners would not have gone ahead and ordered plastic to make this sort of volume, if Cytiva etc had not Said we are good to go!!

Bruker presentation on Monday the 20th.
https://www.labroots.com/webinar/fluorotype-technology-reliable-diagnostic-tool-covid-19-flu-season

https://www.labroots.com/webinar/fluorotype-technology-reliable-diagnostic-tool-covid-19-flu-seasonBruker presenning Monday the 20th

U.K. order is 10x that

I note various contributors to the board, are attempting to more the Price Down, only to take advantge of this later this week!

I Think you will find it was the annual redemption period for Miton and the company chose to take profits in various holdings incl. Avacta.
Miton is still a substantial shareholder and I am sure will be looking like other significant shareholders like Sequioa etc.forward To a quite unique Q4 and with shareholder returns of a scale not found in many plades across the Markets .

As the ceo has explain, ongoing discussions with several manufacturers.

130,000 bought at 182. One print, post market order